Amgen's biosimilar candidate ABP 501 has shown comparable results in phase III, measured against AbbVie's blockbuster Humira (adalimumab), for patients with moderate-to-severe plaque psoria
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
